Com­pa­nies flail amid broad biotech fall­out; Sick­le cell reck­on­ing; Fol­low-up on Pfiz­er's CRO trou­ble; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Over the next few weeks you may see us start­ing to ex­per­i­ment with some new for­mats and ways of re­cap­ping news sto­ries. Don’t hes­i­tate to send me your thoughts — I would love your feed­back.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.